MedTrace Logo

Testing the Effect of a Warning About New Drugs

NCT00950131 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2944

Last updated 2010-04-09

No results posted yet for this study

Summary

The purpose of this study is to test whether a new drug warning decreases enthusiasm for new drugs.

Conditions

  • Risk Communication

Interventions

OTHER

Presentation of information about drug approval and level of warning

Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning

Sponsors & Collaborators

  • Attorney General Consumer & Prescriber Education Grant

    collaborator OTHER

  • White River Junction Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Lisa M Schwartz, MD, MS · White River Junction Veterans Affairs Medical Center

  • Steven Woloshin, MD, MS · White River Junction Veterans Affairs Medical Center

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-08-31
Completion
2009-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00950131 on ClinicalTrials.gov